BioCentury
ARTICLE | Financial News

Sienna's series B round brings in $40M

April 25, 2017 9:19 PM UTC

Dermatology company Sienna Biopharmaceuticals Inc. (Westlake Village, Calif.) raised $40 million in a series B round led by Arch Venture Partners and Venvest Capital. Also participating were Partner Fund Management, Altitude Life Science Ventures, former Allergan Inc. Chairman and CEO David Pyott, Fidelity Management & Research Company, Clough Capital Partners, Omega Fund Management, and other undisclosed investors.

The company’s lead candidate, SNA-120, is in Phase IIb testing to treat pruritus and psoriasis. SNA-120 is a topical neurotrophic tyrosine kinase receptor 1 (TrkA; NTRK1) inhibitor. Sienna said it also plans to develop SNA-125, a TrkA and Janus kinase-3 (JAK-3) inhibitor, for atopic dermatitis, psoriasis, and pruritus. The company did not respond to inquiries...

BCIQ Company Profiles

Sienna Biopharmaceuticals Inc.